IP Gaia will generate composition of matter patents for new chemical entities by conducting non-clinical research and development activities and make variety of transactions mainly with pharmaceutical companies. IP Gaia has already concluded a comprehensive partnership agreement with Axcelead, Inc. and Axcelead Drug Discovery Partners, Inc. By collaborating among the parties to build a next stage drug discovery platform, it would be possible to generate high quality innovative pharmaceuticals in a shorter period of time and lower cost. As for the pharmaceutical industry, the trend of the horizontal division of labor business model would be more accelerating. IPGaia plays a role as a platformer for creating pre-clinical stage innovative new medicines.

свернуть